Short Interest in Akers Biosciences Inc (AKER) Declines By 63.3%

Akers Biosciences Inc (NASDAQ:AKER) was the recipient of a significant decline in short interest in the month of December. As of December 29th, there was short interest totalling 194,099 shares, a decline of 63.3% from the December 15th total of 529,598 shares. Approximately 0.9% of the company’s shares are short sold. Based on an average daily volume of 3,936,865 shares, the days-to-cover ratio is currently 0.0 days.

Akers Biosciences (AKER) opened at $0.18 on Friday. The stock has a market cap of $4.58, a P/E ratio of -0.31 and a beta of -0.38. Akers Biosciences has a 1-year low of $0.12 and a 1-year high of $2.90.

Akers Biosciences (NASDAQ:AKER) last issued its quarterly earnings data on Wednesday, November 15th. The medical instruments supplier reported ($0.13) earnings per share (EPS) for the quarter. The firm had revenue of $0.68 million for the quarter. Akers Biosciences had a negative net margin of 134.31% and a negative return on equity of 94.44%.

Separately, ValuEngine upgraded shares of Akers Biosciences from a “sell” rating to a “hold” rating in a report on Friday, December 1st.

ILLEGAL ACTIVITY WARNING: “Short Interest in Akers Biosciences Inc (AKER) Declines By 63.3%” was first posted by Markets Daily and is the property of of Markets Daily. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.themarketsdaily.com/2018/01/14/short-interest-in-akers-biosciences-inc-aker-declines-by-63-3.html.

About Akers Biosciences

Akers Biosciences, Inc, together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States and internationally. The company’s marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness.

Receive News & Ratings for Akers Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akers Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply